Cargando…

Treatment with Shuyu capsule increases 5-HT1AR level and activation of cAMP-PKA-CREB pathway in hippocampal neurons treated with serum from a rat model of depression

Depressive disorder (DD) is one of the typical affective disorders with a high morbidity, high suicide rate and high recurrence rate. Dysfunction of the 5-hydroxytryptamine 1A receptor (5-HT1AR) in the brain may serve an important role in the pathogenesis of DD. Currently, selective serotonin reupta...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiao-Long, Gao, Jie, Wang, Xiao-Yu, Mu, Xiao-Fei, Wei, Sheng, Xue, Ling, Qiao, Ming-Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802157/
https://www.ncbi.nlm.nih.gov/pubmed/29286104
http://dx.doi.org/10.3892/mmr.2017.8339
_version_ 1783298488621072384
author Wang, Xiao-Long
Gao, Jie
Wang, Xiao-Yu
Mu, Xiao-Fei
Wei, Sheng
Xue, Ling
Qiao, Ming-Qi
author_facet Wang, Xiao-Long
Gao, Jie
Wang, Xiao-Yu
Mu, Xiao-Fei
Wei, Sheng
Xue, Ling
Qiao, Ming-Qi
author_sort Wang, Xiao-Long
collection PubMed
description Depressive disorder (DD) is one of the typical affective disorders with a high morbidity, high suicide rate and high recurrence rate. Dysfunction of the 5-hydroxytryptamine 1A receptor (5-HT1AR) in the brain may serve an important role in the pathogenesis of DD. Currently, selective serotonin reuptake inhibitors are the first line antidepressants with 60–70% efficacy and severe adverse effects. Previous studies have demonstrated that Chinese herbal medicines, including the Shuyu capsule (SYC), are effective antidepressants with few side effects. However, the mechanism remains unclear. In the present study, the effects of the SYC on the 5-HT1AR level and the activation of adenylyl cyclase-cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA)-cAMP response element-binding (CREB) signaling pathway that 5-HT1AR mediates in the cells of hippocampal neurons were investigated in vitro. The SYC demonstrated an antidepressant effect similar to that of fluoxetine in a rat depression model. Treatment of hippocampal neurons with the serum of depressive rats resulted in a decrease in the 5-HT1AR protein level and the activation of the cAMP-PKA-CREB signaling pathway in hippocampal neurons. Exposure to the serum of rats that received chronic mild stress plus SYC treatment led to no alterations in the 5-HT1AR level or the activation of the cAMP-PKA-CREB signaling pathway compared with those of cells exposed to normal rat serum. This effect is similar to the effects of 5-HT1AR antagonist WAY-100635. In addition, the 5-HT1A agonist 8-hydroxy-(dipropylamino) tetralin did not antagonize the effects of the SYC. Furthermore, the SYC exhibited an increased effect compared with fluoxetine on 5-HT1AR levels and CREB activation. The present study suggested that the SYC functions by increasing 5-HT1AR protein levels and the activation of the 5-HT1AR-mediated cAMP-PKA-CREB signaling pathway in hippocampal neurons.
format Online
Article
Text
id pubmed-5802157
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-58021572018-02-26 Treatment with Shuyu capsule increases 5-HT1AR level and activation of cAMP-PKA-CREB pathway in hippocampal neurons treated with serum from a rat model of depression Wang, Xiao-Long Gao, Jie Wang, Xiao-Yu Mu, Xiao-Fei Wei, Sheng Xue, Ling Qiao, Ming-Qi Mol Med Rep Articles Depressive disorder (DD) is one of the typical affective disorders with a high morbidity, high suicide rate and high recurrence rate. Dysfunction of the 5-hydroxytryptamine 1A receptor (5-HT1AR) in the brain may serve an important role in the pathogenesis of DD. Currently, selective serotonin reuptake inhibitors are the first line antidepressants with 60–70% efficacy and severe adverse effects. Previous studies have demonstrated that Chinese herbal medicines, including the Shuyu capsule (SYC), are effective antidepressants with few side effects. However, the mechanism remains unclear. In the present study, the effects of the SYC on the 5-HT1AR level and the activation of adenylyl cyclase-cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA)-cAMP response element-binding (CREB) signaling pathway that 5-HT1AR mediates in the cells of hippocampal neurons were investigated in vitro. The SYC demonstrated an antidepressant effect similar to that of fluoxetine in a rat depression model. Treatment of hippocampal neurons with the serum of depressive rats resulted in a decrease in the 5-HT1AR protein level and the activation of the cAMP-PKA-CREB signaling pathway in hippocampal neurons. Exposure to the serum of rats that received chronic mild stress plus SYC treatment led to no alterations in the 5-HT1AR level or the activation of the cAMP-PKA-CREB signaling pathway compared with those of cells exposed to normal rat serum. This effect is similar to the effects of 5-HT1AR antagonist WAY-100635. In addition, the 5-HT1A agonist 8-hydroxy-(dipropylamino) tetralin did not antagonize the effects of the SYC. Furthermore, the SYC exhibited an increased effect compared with fluoxetine on 5-HT1AR levels and CREB activation. The present study suggested that the SYC functions by increasing 5-HT1AR protein levels and the activation of the 5-HT1AR-mediated cAMP-PKA-CREB signaling pathway in hippocampal neurons. D.A. Spandidos 2018-03 2017-12-22 /pmc/articles/PMC5802157/ /pubmed/29286104 http://dx.doi.org/10.3892/mmr.2017.8339 Text en Copyright: © Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Wang, Xiao-Long
Gao, Jie
Wang, Xiao-Yu
Mu, Xiao-Fei
Wei, Sheng
Xue, Ling
Qiao, Ming-Qi
Treatment with Shuyu capsule increases 5-HT1AR level and activation of cAMP-PKA-CREB pathway in hippocampal neurons treated with serum from a rat model of depression
title Treatment with Shuyu capsule increases 5-HT1AR level and activation of cAMP-PKA-CREB pathway in hippocampal neurons treated with serum from a rat model of depression
title_full Treatment with Shuyu capsule increases 5-HT1AR level and activation of cAMP-PKA-CREB pathway in hippocampal neurons treated with serum from a rat model of depression
title_fullStr Treatment with Shuyu capsule increases 5-HT1AR level and activation of cAMP-PKA-CREB pathway in hippocampal neurons treated with serum from a rat model of depression
title_full_unstemmed Treatment with Shuyu capsule increases 5-HT1AR level and activation of cAMP-PKA-CREB pathway in hippocampal neurons treated with serum from a rat model of depression
title_short Treatment with Shuyu capsule increases 5-HT1AR level and activation of cAMP-PKA-CREB pathway in hippocampal neurons treated with serum from a rat model of depression
title_sort treatment with shuyu capsule increases 5-ht1ar level and activation of camp-pka-creb pathway in hippocampal neurons treated with serum from a rat model of depression
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802157/
https://www.ncbi.nlm.nih.gov/pubmed/29286104
http://dx.doi.org/10.3892/mmr.2017.8339
work_keys_str_mv AT wangxiaolong treatmentwithshuyucapsuleincreases5ht1arlevelandactivationofcamppkacrebpathwayinhippocampalneuronstreatedwithserumfromaratmodelofdepression
AT gaojie treatmentwithshuyucapsuleincreases5ht1arlevelandactivationofcamppkacrebpathwayinhippocampalneuronstreatedwithserumfromaratmodelofdepression
AT wangxiaoyu treatmentwithshuyucapsuleincreases5ht1arlevelandactivationofcamppkacrebpathwayinhippocampalneuronstreatedwithserumfromaratmodelofdepression
AT muxiaofei treatmentwithshuyucapsuleincreases5ht1arlevelandactivationofcamppkacrebpathwayinhippocampalneuronstreatedwithserumfromaratmodelofdepression
AT weisheng treatmentwithshuyucapsuleincreases5ht1arlevelandactivationofcamppkacrebpathwayinhippocampalneuronstreatedwithserumfromaratmodelofdepression
AT xueling treatmentwithshuyucapsuleincreases5ht1arlevelandactivationofcamppkacrebpathwayinhippocampalneuronstreatedwithserumfromaratmodelofdepression
AT qiaomingqi treatmentwithshuyucapsuleincreases5ht1arlevelandactivationofcamppkacrebpathwayinhippocampalneuronstreatedwithserumfromaratmodelofdepression